2B78:XETRA:XETRA-iShares Healthcare Innovation UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 7.103

Change

+0.07 (+0.95)%

Market Cap

USD 1.11B

Volume

0.04M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.60 (+1.20%)

USD 450.46B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.19 (+1.23%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.24 (+0.94%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.31 (+1.15%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.27 (+1.14%)

USD 157.79B
TM5:XETRA T-MOBILE US INC.DL-00001

-0.52 (-0.34%)

USD 126.93B
8R80:XETRA Amundi Index Solutions - Amund..

+2.54 (+1.86%)

USD 104.09B
JARI:XETRA Amundi Index Solutions - Amund..

+0.38 (+0.89%)

USD 101.29B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.60 (+1.21%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+10.20 (+2.07%)

USD 80.38B

ETFs Containing 2B78:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.16% 50% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.16% 50% F 52% F
Trailing 12 Months  
Capital Gain 6.57% 42% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.57% 41% F 45% F
Trailing 5 Years  
Capital Gain 21.69% 47% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.69% 47% F 48% F
Average Annual (5 Year Horizon)  
Capital Gain 6.43% 65% D 63% D
Dividend Return 6.43% 64% D 60% D-
Total Return N/A 2% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 22.46% 18% F 30% F
Risk Adjusted Return 28.64% 49% F 50% F
Market Capitalization 1.11B 81% B- 72% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.